Grifols – a Barcelona-based specialist in plasma-based therapies – said today that Tavlesse is the first and only SYK inhibitor for patients with ITP, an autoimmune clotting disorder that ...

Additionally, the trial will explore the mechanisms by which fostamatinib, through SYK inhibition ... treating chronic immune thrombocytopenia (ITP) in adults who have not responded to previous ...

Below is Validea's guru fundamental report for STRYKER CORP (SYK). Of the 22 guru strategies we follow, SYK rates highest using our P/B Growth Investor model based on the published strategy of ...

Syk is responsible for the intracellular propagation ... An earlier phase 2 trial of the drug in patients with immune thrombocytopenic purpura (ITP), an autoimmune condition that destroys blood ...

Stryker Corporation’s SYK shares closed the trading session at $385.18 on Friday, 5.2% below its 52-week high of $406.19 reached on Jan. 28, 2025. In the past six months, SYK has gained 13%.

The drug is the only approved oral SYK inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.